We provide you with 20 years of free, institutional-grade data for NXTC stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of NXTC. Explore the full financial landscape of NXTC stock.
| Reported Date | CIK | Ticker | Type |
|---|
NextCure, Inc(NASDAQ:NXTC) 
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment o...
Website: http://www.nextcure.com
IPO Price: $15 (May 08, 2019)
Full Time Employees: 69
CEO: Michael S. Richman
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about NXTC stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.